EVO Evotec SE

23.73
+0.4  (+2%)
Previous Close 23.33
Open 23.79
52 Week Low 19.94998
52 Week High 35.366631
Market Cap $8,253,993,608
Shares 347,829,482
Float 347,829,482
Enterprise Value $8,188,777,728
Volume 36,378
Av. Daily Volume 200,040
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
EXS-21546
High adenosine signature cancers
Phase 1
Phase 1
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Drug Pipeline

Drug Stage Notes
TPM203
Pemphigus Vulgaris
Phase 1
Phase 1
Phase 1 trial ongoing.
DSP-118
Obsessive compulsive disorder
Phase 1
Phase 1
Phase 1 trial ongoing.
EVT894
Chikungunya
Phase 1
Phase 1
Phase 1 trial ongoing.
CNTX 6016
Pain (CB2)
Phase 1
Phase 1
Phase 1 trial ongoing.

Latest News

  1. EQRx to leverage Evotec's unique data-driven integrated drug discovery and development accelerator platform; partnership aims to build up jointly owned pipeline to deliver innovative, affordable and accessible medicines to patients

    EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, and Evotec SE ((Frankfurt Stock Exchange: EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO), a leading life science company, today announced a collaboration to design, discover and develop new therapeutic options for patients. The collaboration will help accelerate EQRx's pipeline expansion efforts by leveraging Evotec's unique data-driven, fully integrated R&D platform, applied…

    EQRx to leverage Evotec's unique data-driven integrated drug discovery and development accelerator platform; partnership aims to build up jointly owned pipeline to deliver innovative, affordable and accessible medicines to patients

    EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, and Evotec SE ((Frankfurt Stock Exchange: EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO), a leading life science company, today announced a collaboration to design, discover and develop new therapeutic options for patients. The collaboration will help accelerate EQRx's pipeline expansion efforts by leveraging Evotec's unique data-driven, fully integrated R&D platform, applied across different drug modalities and therapeutic areas. This approach aims to expedite the invention and development of novel drugs and helps ensure superior translation from research ideas to safe and efficacious medicines.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211118005421/en/

    The collaboration will focus on multiple therapeutic targets in oncology and immunology. Under the terms of the agreement, EQRx and Evotec will collaborate on drug discovery, pre-clinical and clinical development. Evotec will lead drug discovery and pre-clinical development efforts, and EQRx will be responsible for clinical development, regulatory and commercialization efforts. In addition to jointly funded research and development activities, Evotec will benefit from the potential commercial success of the assets developed within the partnership through a variable profit share mechanism.

    "We continue to rapidly expand our early-stage development pipeline through access to innovative, next-generation drug discovery and engineering technologies," said Carlos Garcia-Echeverria, Ph.D., chief of Rx creation at EQRx. "This collaboration with Evotec will enable us to engineer and develop precision medicines in immunology and oncology with high quality and speed of execution. We look forward to a productive collaboration to bring innovative, affordable and accessible treatment options to people in need."

    "EQRx's ambitious and transformative mission to deliver important new therapies to patients at more affordable prices makes them an ideal partner for us," commented Dr. Craig Johnstone, chief operating officer of Evotec. "This exciting new partnership will expand the reach of our unique data-driven integrated R&D platform. We look forward to leveraging our combined knowledge, expertise and leading-edge technologies to advance new medicines against validated targets as rapidly as possible to make the biggest possible impact for patients."

    About EQRx

    EQRx is a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices. Launched in January 2020, EQRx is purpose-built, at scale, with a growing catalog of medicines in development in high-cost drug categories and emerging partnerships with leading payers and providers. Leveraging cutting-edge science and technology and strategic partnerships with stakeholders from across the healthcare system, EQRx aims to provide innovative, patent-protected medicines more efficiently and cost-effectively than ever before. In August 2021, EQRx announced a proposed combination with CM Life Sciences III (NASDAQ:CMLTU) to accelerate its growth. The combination is expected to be completed in the fourth quarter of 2021. To learn more, visit www.eqrx.com and follow us on social media: Twitter: @EQRxInc, LinkedIn, Instagram: @eqrxinc.

    EQRx™ and Remaking Medicine™ are trademarks of EQRx, Inc.

    About Evotec SE

    Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this "Data-driven R&D Autobahn to Cures" for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g., neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 3,900 highly qualified people. The Company's 14 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to http://www.evotec.com and follow us on Twitter @Evotec and LinkedIn.

    EQRx Cautionary Statement Regarding Forward-Looking Statements

    This communication contains certain forward-looking statements within the meaning of the federal securities laws with respect to the proposed transaction between EQRx and CM Life Sciences III, including express or implied statements regarding the ability to consummate the transaction and become a public company, as well as EQRx's ability to accelerate growth and expand access to innovative medicines, EQRx's ability to obtain FDA and other approvals of any product candidates in its pipeline, ability to expand its pipeline, and execute on its business strategy with payers, as well as other statements regarding plans and market opportunities of EQRx. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) the risk that the transaction may not be completed in a timely manner or at all, (ii) the risk that the transaction may not be completed by CM Life Sciences III's business combination deadline and the potential failure to obtain an extension of the business combination deadline if sought by CM Life Sciences III, (iii) the failure to satisfy the conditions to the consummation of the transaction, including the adoption of the merger agreement by the stockholders of CM Life Sciences III, the satisfaction of the minimum trust account amount following redemptions by CM Life Sciences III's public stockholders and the receipt of certain governmental and regulatory approvals, (iv) the lack of a third-party valuation in determining whether or not to pursue the transaction, (v) the inability to complete the PIPE investment in connection with the transaction, (vi) the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement, (vii) the effect of the announcement or pendency of the transaction on EQRx's business relationships, operating results and business generally, (viii) risks that the proposed transaction disrupts current plans and operations of EQRx and potential difficulties in EQRx employee retention as a result of the transaction, (ix) the outcome of any legal proceedings that may be instituted against CM Life Sciences III or EQRx related to the merger agreement or the transaction, (x) the ability to maintain the listing of CM Life Sciences III's securities on a national securities exchange, (xi) changes in the competitive and highly regulated industries in which EQRx operates, variations in operating performance across competitors, changes in laws and regulations affecting EQRx's business and changes in the combined capital structure, (xii) risks associated with EQRx's ability to implement its business plans, including risks associated with its growth strategy, obtaining regulatory approvals, and creating a global payer network, and other risks associating with its plans to create a new kind of pharmaceutical company, (xiii) the risk of downturns and a changing regulatory landscape in the highly competitive healthcare and biopharmaceutical industries, (xiv) the size and growth of the markets in which EQRx operates and its ability to offer innovative medicines at reduced prices, and (xv) EQRx's ability to operate as a public company. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of the proxy statement/prospectus included in the registration statement on Form S-4 (File No. 333-259054) filed with the SEC in connection with the transaction and other documents filed by CM Life Sciences III from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and EQRx and CM Life Sciences III assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Neither EQRx nor CM Life Sciences III gives any assurance that either EQRx or CM Life Sciences III or the combined company will achieve its expectations.

    Additional Information and Where to Find It / Non-Solicitation

    In connection with the proposed transaction, CM Life Sciences III filed a registration statement on Form S-4 (File No. 333-259054) with the SEC including the preliminary proxy statement/prospectus. The definitive proxy statement/prospectus will be sent to the stockholders of CM Life Sciences III. CM Life Sciences III and EQRx also will file other documents regarding the proposed transaction with the SEC. Before making any voting decision, investors and security holders of CM Life Sciences III are urged to read the registration statement, the proxy statement/prospectus, and all other relevant documents filed or that will be filed with the SEC in connection with the proposed transaction as they become available because they will contain important information about the proposed transaction. Investors and security holders will be able to obtain free copies of the registration statement, the proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC by CM Life Sciences III and EQRx through the website maintained by the SEC at http://www.sec.gov.

    The documents filed by CM Life Sciences III with the SEC also may be obtained free of charge at CM Life Sciences III's website at https://iii.cmlifesciencesspac.com/ or upon written request to CM Life Sciences III, c/o Corvex Management, 667 Madison Ave, New York, NY 10065.

    Participants in Solicitation

    CM Life Sciences III and EQRx and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from CM Life Sciences III's stockholders in connection with the proposed transaction. Information about CM Life Sciences III's directors and executive officers and their ownership of CM Life Sciences III's securities is set forth in CM Life Sciences III's filings with the SEC. To the extent that holdings of CM Life Sciences III's securities have changed since the amounts printed in CM Life Sciences III's Registration Statement on Form S-1, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC. A list of the names of such directors and executive officers and information regarding their interests in the business combination will be contained in the proxy statement/prospectus when available. You may obtain free copies of these documents as described in the preceding paragraph.

    No Offer or Solicitation

    This communication is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the potential transaction and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, or an exemption therefrom.

    Evotec Forward-Looking Statements

    This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding completion of the offering. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

    View Full Article Hide Full Article
    • EQRX TO LEVERAGE EVOTEC'S UNIQUE DATA-DRIVEN INTEGRATED DRUG DISCOVERY AND DEVELOPMENT ACCELERATOR PLATFORM
    • PARTNERSHIP AIMS TO BUILD UP JOINTLY OWNED PIPELINE TO DELIVER INNOVATIVE, AFFORDABLE AND ACCESSIBLE MEDICINES TO PATIENTS

    HAMBURG, GERMANY, and CAMBRIDGE, MA / ACCESSWIRE / November 18, 2021 / Evotec SE ((Frankfurt Stock Exchange: EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) and EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today announced a collaboration to design, discover and develop new therapeutic options for patients. The collaboration will help accelerate EQRx's pipeline expansion efforts by leveraging Evotec's unique data-driven, fully…

    • EQRX TO LEVERAGE EVOTEC'S UNIQUE DATA-DRIVEN INTEGRATED DRUG DISCOVERY AND DEVELOPMENT ACCELERATOR PLATFORM
    • PARTNERSHIP AIMS TO BUILD UP JOINTLY OWNED PIPELINE TO DELIVER INNOVATIVE, AFFORDABLE AND ACCESSIBLE MEDICINES TO PATIENTS

    HAMBURG, GERMANY, and CAMBRIDGE, MA / ACCESSWIRE / November 18, 2021 / Evotec SE ((Frankfurt Stock Exchange: EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) and EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today announced a collaboration to design, discover and develop new therapeutic options for patients. The collaboration will help accelerate EQRx's pipeline expansion efforts by leveraging Evotec's unique data-driven, fully integrated R&D-platform, applied across different drug modalities and therapeutic areas. This approach aims to expedite the invention and development of novel drugs and helps ensure superior translation from research ideas to safe and efficacious medicines.

    The collaboration will focus on multiple therapeutic targets in oncology and immunology. Under the terms of the agreement, EQRx and Evotec will collaborate on drug discovery, pre-clinical and clinical development. Evotec will lead drug discovery and pre-clinical development efforts, and EQRx will be responsible for clinical development, regulatory and commercialisation efforts. In addition to jointly funded research and development activities, Evotec will benefit from the potential commercial success of the assets developed within the partnership through a variable profit share mechanism.

    Dr Craig Johnstone, Chief Operating Officer of Evotec, commented: "EQRx's ambitious and transformative mission to deliver important new therapies to patients at more affordable prices makes them an ideal partner for us. This exciting new partnership will expand the reach of our unique data-driven integrated R&D platform. We look forward to leveraging our combined knowledge, expertise and leading-edge technologies to advance new medicines against validated targets as rapidly as possible to make the biggest possible impact for patients."

    "We continue to rapidly expand our early-stage development pipeline through access to innovative, next-generation drug discovery and engineering technologies," said Carlos Garcia-Echeverria, PhD, chief of Rx creation at EQRx. "This collaboration with Evotec will enable us to engineer and develop precision medicines in immunology and oncology with high quality and speed of execution. We look forward to a productive collaboration to bring innovative, affordable and accessible treatment options to people in need."

    ABOUT EQRx
    EQRx is a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices. Launched in January 2020, EQRx is purpose-built, at scale, with a growing catalog of medicines in development in high-cost drug categories and emerging partnerships with leading payers and providers. Leveraging cutting-edge science and technology and strategic partnerships with stakeholders from across the healthcare system, EQRx aims to provide innovative, patent-protected medicines more efficiently and cost-effectively than ever before. In August 2021, EQRx announced a proposed combination with CM Life Sciences III (NASDAQ:CMLTU) to accelerate its growth. The combination is expected to be completed in the fourth quarter of 2021. To learn more, visit www.eqrx.com and follow us on social media: Twitter: @EQRxInc , LinkedIn , Instagram: @eqrxinc . EQRx(TM) and Remaking Medicine(TM) are trademarks of EQRx, Inc.

    ABOUT EVOTEC SE
    Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this "Data-driven R&D Autobahn to Cures" for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 4,000 highly qualified people. The Company's 14 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on Twitter @Evotec and LinkedIn .

    FORWARD-LOOKING STATEMENTS
    This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding completion of the offering. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

    SOURCE: Evotec AG



    View source version on accesswire.com:
    https://www.accesswire.com/673559/Evotec-and-EQRx-Announce-Integrated-Drug-Discovery-and-Development-Partnership

    View Full Article Hide Full Article
    • STRONG OPERATIONAL PERFORMANCE LEADS TO SIGNIFICANT REVENUE GROWTH
    • CO-OWNED PIPELINE GAINING MOMENTUM
    • J.POD (R) REDMOND (US) OPERATIONAL
    • SUCCESSFUL PUBLIC OFFERING AT NASDAQ (AFTER PERIOD-END)
    • GUIDANCE FOR FULL-YEAR 2021 CONFIRMED
    • WEBCAST AND CONFERENCE CALL TODAY AT 02.00 PM CET

    HAMBURG, GERMANY / ACCESSWIRE / November 11, 2021 / Evotec SE ((Frankfurt Stock Exchange: EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) today announced the financial results and corporate updates for the first nine months 2021.

    HIGHLIGHTS

    STRONG REVENUES GROWTH IN ALL BUSINESS AREAS FUELS ONGOING EXPANSION AND STRENGTHENS POSITIVE DEVELOPMENT

    • Group revenues increased by 20% to € 431.0 m (9M 2020: € 360.4 m); like-for-like base revenue growth (excluding portfolio and fx effects) up…
    • STRONG OPERATIONAL PERFORMANCE LEADS TO SIGNIFICANT REVENUE GROWTH
    • CO-OWNED PIPELINE GAINING MOMENTUM
    • J.POD (R) REDMOND (US) OPERATIONAL
    • SUCCESSFUL PUBLIC OFFERING AT NASDAQ (AFTER PERIOD-END)
    • GUIDANCE FOR FULL-YEAR 2021 CONFIRMED
    • WEBCAST AND CONFERENCE CALL TODAY AT 02.00 PM CET

    HAMBURG, GERMANY / ACCESSWIRE / November 11, 2021 / Evotec SE ((Frankfurt Stock Exchange: EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) today announced the financial results and corporate updates for the first nine months 2021.

    HIGHLIGHTS

    STRONG REVENUES GROWTH IN ALL BUSINESS AREAS FUELS ONGOING EXPANSION AND STRENGTHENS POSITIVE DEVELOPMENT

    • Group revenues increased by 20% to € 431.0 m (9M 2020: € 360.4 m); like-for-like base revenue growth (excluding portfolio and fx effects) up 26%
    • Milestone revenues of € 27.9 m well above last year (9M 2020: € 8.4 m)
    • Just - Evotec Biologics contributed € 34.7 m to revenues; 43% above last year's level of € 24.3 m
    • Strong progress in both segments: Total EVT Execute revenues up 17% to € 429.8 m (9M 2020: € 367.5 m); EVT Innovate revenues up 35% to € 101.9 m (9M 2020: € 75.7 m)
    • Adjusted Group EBITDA of € 70.1 m (9M 2020: € 76.9 m) primarily driven by higher costs of sales ahead of production start of J.POD (R) Redmond (US), a deliberate increase in unpartnered R&D (up 28%), the overall growth of Evotec and effects from the US public offering; like-for-like growth (excluding portfolio and fx effects) would have reached 16%.
    • Other non-operating result increased significantly to € 228.8 m (9M 2020: € (15.9) m) mainly due to fair value adjustments of the equity participation in Exscientia Ltd.

    DATA-DRIVEN AUTOBAHN TO CURES: STRONG PROGRESS IN ALL LANES

    • Several new and extended drug discovery and development agreements in all areas
    • Just - Evotec Biologics opened J.POD (R) Redmond (US); start operations on track; project initiation of J.POD (R) Toulouse (France) in 2021
    • Positive Phase IIb results in refractory chronic cough for eliapixant reported by partner Bayer
    • Excellent progress in iPSC and protein degradation collaborations with Bristol Myers Squibb (BMS); Opt-in for EVT8683 to enter clinical development
    • Kazia Therapeutics Limited has commenced enrolment to a Phase I clinical trial of EVT801, an investigational cancer therapy (after period-end)
    • Successful NASDAQ IPO of EVO equity portfolio company and partner Exscientia Ltd (after period-end); Series B extension by Evotec's first spin-off Topas Therapeutics

    CORPORATE

    • Closing of public offering at NASDAQ on 08 November 2021, with notice from underwriters on 05 November 2021 of their intention to partially exercise their option to purchase additional ADSs (after period-end)

    CONFIRMATION OF BUSINESS OUTLOOK FOR FULL-YEAR 2021 AND MID-TERM TARGETS 2025

    • Group revenues expected to be in a range of € 550 - 570 m (€ 565 - 585 m at constant exchange rates) (2020: € 500.9 m)
    • Adjusted Group EBITDA expected to be in the range of € 105 - 120 m (€ 115 - 130 m at constant exchange rates) (2020: € 106.6 m)
    • Unpartnered research and development expenses expected to be in a range of € 50 - 60 m (2020: € 46.4 m)
    • Mid-term goals target revenue growth to > € 1,000 m, adjusted EBITDA of >= € 300 m and unpartnered research and development expenses of > € 100 m by 2025

    Given current global insecurities surrounding the COVID-19 pandemic, a likely negative impact - though less pronounced than in 2020 - is already estimated within the guidance for revenues and adjusted EBITDA stated above.

    More detailed information and financial tables are available in our nine-month report published on the Evotec website under the following link: https://www.evotec.com/en/investor-relations/publications

    FINANCIAL HIGHLIGHTS

    The following table provides an overview of the financial performance in the first nine months of 2021 compared to the same period in 2020.

    Key figures of consolidated income statement & segment information>
    Evotec SE & subsidiaries - First nine months of 2021



    In T€


    EVT
    Execute4)


    EVT
    Innovate5)


    Intersegment Eliminations

    Evotec Group
    9M 2021

    Evotec Group
    9M 2020

    External revenues1)

    329,023

    101,940

    -

    430,963

    360,414

    Intersegment revenues

    100,751

    -

    (100,751)

    -

    -

    Costs of revenues

    (343,418)

    (79,781)

    91,705

    (331,494)

    (271.225)

    Gross profit

    86,356

    22,159

    (9,046)

    99,469

    89,189

    Gross margin in %

    20.1

    21.7

    -

    23.1

    24.7

    R&D expenses2)

    (2,120)

    (60,398)

    9,046

    (53,472)

    (46,077)

    SG&A expenses

    (56,714)

    (14,323)

    -

    (71,037)

    (58,132)

    Impairments of intangible assets and goodwill


    -


    (683)


    -


    (683)


    -

    Other operating
    income (expenses), net


    17,539


    34,237

    -


    51,776


    50,306

    Operating result

    45,061

    (19,008)

    -

    26,053

    35,286

    Adjusted EBITDA3)

    85,985

    (15,899)

    -

    70,086

    76,942

    1. Adjusted for negative exchange rate effects of € 11.2 m, Group revenues amount to € 442.1 m
    2. Of which unpartnered R&D expenses of € 42.6 m in 9M 2021 (9M 2020: € 33.4 m)
    3. Before changes in contingent considerations, income from bargain purchase and excluding impairments on goodwill, other intangible and tangible assets as well as the total non-operating result
    4. Revenues from material recharges of € 23.6 m are allocated to EVT Execute as of 9M 2021
    5. Revenues from material recharges of € 1.2m are allocated to EVT Innovate as of 9M 2021

    WEBCAST / CONFERENCE CALL

    The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference call will be held in English.

    Conference call details
    Date: Thursday, 11 November 2021
    Time: 02.00 pm CET (08.00 am ET, 01.00 pm GMT)

    From Germany: +49 69 20 17 44 220
    From France: +33 170 709 502
    From Italy: +39 023 600 6663
    From Switzerland: +41 445 806 522
    From UK: +44 20 3009 2470
    From USA: +1 877 423 0830
    Access Code: 82123163#

    A simultaneous slide presentation for participants dialling in via phone is available at https://www.webcast-eqs.com/evotec20211111/no-audio .

    Webcast details
    To join the audio webcast and to access the presentation slides you will find a link on our homepage http://www.evotec.com shortly before the event.

    A replay of the conference call will be available for seven days and can be accessed from Germany by dialling +49 69 201744221, from UK by dialling +44 20 3364 5150 and from USA by dialling +1 (844) 307-9362.

    The access code is 315614529#. The on-demand version of the webcast will be available on our website: https://www.evotec.com/en/investor-relations/publications and under the direct link https://www.webcast-eqs.com/evotec20211111 .

    ABOUT EVOTEC SE
    Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this "Data-driven R&D Autobahn to Cures" for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 4,000 highly qualified people. The Company's 14 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on Twitter @Evotec and LinkedIn .

    FORWARD-LOOKING STATEMENTS
    This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding completion of the offering. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

    IR Contact Evotec SE:
    Volker Braun, SVP Head of Global Investor Relations & ESG, Phone: +49.(0)40.56081-775,

    SOURCE: Evotec AG



    View source version on accesswire.com:
    https://www.accesswire.com/672312/Evotec-SE-Reports-Results-for-the-First-Nine-Months-2021-and-Provides-Corporate-Update

    View Full Article Hide Full Article
    • THE DESIGNATION OF ADDITIONAL PROGRAMMES BY BRISTOL MYERS SQUIBB TRIGGERED PAYMENTS OF IN TOTAL US$ 40 M TO EVOTEC

    HAMBURG, GERMANY / ACCESSWIRE / November 10, 2021 / Evotec SE ((Frankfurt Stock Exchange:EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) announced today that the Company reached additional programme designations within its neuroscience collaboration with Bristol Myers Squibb (NYSE:BMY) triggering payments of in total US$ 40 m to Evotec.

    These target-based programme designations further bolster the growing pipeline and are expected to follow EVT8683, which Bristol Myers Squibb opted to license after the successful filing of an IND application with the FDA.

    Dr Cord Dohrmann, Chief Scientific Officer of Evotec, said: "Our collaboration with…

    • THE DESIGNATION OF ADDITIONAL PROGRAMMES BY BRISTOL MYERS SQUIBB TRIGGERED PAYMENTS OF IN TOTAL US$ 40 M TO EVOTEC

    HAMBURG, GERMANY / ACCESSWIRE / November 10, 2021 / Evotec SE ((Frankfurt Stock Exchange:EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) announced today that the Company reached additional programme designations within its neuroscience collaboration with Bristol Myers Squibb (NYSE:BMY) triggering payments of in total US$ 40 m to Evotec.

    These target-based programme designations further bolster the growing pipeline and are expected to follow EVT8683, which Bristol Myers Squibb opted to license after the successful filing of an IND application with the FDA.

    Dr Cord Dohrmann, Chief Scientific Officer of Evotec, said: "Our collaboration with BMS continues to be highly productive. These achievements are a testimony of the great team spirit between Bristol Myers Squibb and Evotec colleagues that enabled us to advance highly challenging programmes to key value inflection points."

    The collaboration was initiated in December 2016 with the goal of identifying disease-modifying treatments for a broad range of neurodegenerative diseases. Currently approved drugs only offer short-term management of the patients' symptoms and there is a huge unmet medical need for therapeutic modalities that slow down or reverse disease progression. The collaboration leverages Evotec's industrialised iPSC platform using patient-derived disease models, which is one of the largest and most sophisticated platforms in the industry.

    About Evotec and iPSC
    Induced pluripotent stem cells (also known as iPS cells or iPSCs) are a type of pluripotent stem cell that can be generated directly from adult cells. The iPSC technology was pioneered by Shinya Yamanaka's lab in Kyoto, Japan, who showed in 2006 that the introduction of four specific genes encoding transcription factors could convert adult cells into pluripotent stem cells. He was awarded the 2012 Nobel Prize along with Sir John Gurdon "for the discovery that mature cells can be reprogrammed to become pluripotent". Pluripotent stem cells hold great promise in the field of regenerative medicine. Because they can propagate indefinitely, as well as give rise to every other cell type in the body (such as neurons, heart, pancreatic and liver cells), they represent a single source of cells that could be used to replace those lost to damage or disease.

    Evotec has built an industrialised iPSC infrastructure that represents one of the largest and most sophisticated iPSC platforms in the industry. Evotec's iPSC platform has been developed over the last years with the goal to industrialise iPSC-based drug screening in terms of throughput, reproducibility and robustness to reach the highest industrial standards, and to use iPSC-based cells in cell therapy approaches via the Company's proprietary EVO cells platform.

    ABOUT EVOTEC SE
    Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this "Data-driven R&D Autobahn to Cures" for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 4,000 highly qualified people. The Company's 14 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on Twitter @Evotec and LinkedIn .

    FORWARD-LOOKING STATEMENTS
    This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding completion of the offering. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

    Media Contact Evotec SE:
    Gabriele Hansen, SVP Head of Global Corporate Communications & Marketing, Phone: +49.(0)40.56081-255,

    IR Contact Evotec SE:
    Volker Braun, SVP Head of Global Investor Relations & ESG, Phone: +49.(0)40.56081-775,

    SOURCE: Evotec AG



    View source version on accesswire.com:
    https://www.accesswire.com/672074/Evotec-Reaches-Programme-Designations-in-Neuroscience-Collaboration-with-Bristol-Myers-Squibb

    View Full Article Hide Full Article
  2. HAMBURG, GERMANY / ACCESSWIRE / November 9, 2021 / Evotec SE ((Frankfurt Stock Exchange: EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) announced today the closing of its public offering on 08 November 2021 in the United States of 20,000,000 American Depositary Shares ("ADSs"). Each ADS represents half of one ordinary share of Evotec. All ADSs sold in the offering were offered by Evotec at a public offering price of $ 21.75 per ADS.

    On 05 November 2021, BofA Securities and Morgan Stanley, as representatives of the several underwriters, notified Evotec of the underwriters' partial exercise of their option to purchase up to 3,000,000 additional ADSs, representing 1,500,000 ordinary shares (the "Option") at the price of $ 21.75 per ADS. The Option is…

    HAMBURG, GERMANY / ACCESSWIRE / November 9, 2021 / Evotec SE ((Frankfurt Stock Exchange: EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) announced today the closing of its public offering on 08 November 2021 in the United States of 20,000,000 American Depositary Shares ("ADSs"). Each ADS represents half of one ordinary share of Evotec. All ADSs sold in the offering were offered by Evotec at a public offering price of $ 21.75 per ADS.

    On 05 November 2021, BofA Securities and Morgan Stanley, as representatives of the several underwriters, notified Evotec of the underwriters' partial exercise of their option to purchase up to 3,000,000 additional ADSs, representing 1,500,000 ordinary shares (the "Option") at the price of $ 21.75 per ADS. The Option is expected to close on 15 November 2021 and is subject to customary closing conditions.

    In total, Evotec expects the gross proceeds of the transaction to amount to $ 500 million comprising the base offering of 20,000,000 ADSs ($ 435 million) and, upon closing, the exercised Option to purchase 2,995,000 additional ADSs ($ 65 million), before deducting underwriting commissions and estimated offering expenses payable by Evotec.

    Evotec's ordinary shares are listed on the regulated market of the Frankfurt Stock Exchange in Germany with additional admission obligations of the Prime Standard Segment.

    BofA Securities and Morgan Stanley acted as lead joint book-running managers for the public offering. Citigroup, Jefferies, Cowen, and RBC Capital Markets also acted as joint book-running managers for the offering. The ADSs will be issued under Evotec's revised ADS program, which continues to be administered by JP Morgan Chase Bank, N.A.

    A registration statement relating to the ADSs sold in this offering was filed with the U.S. Securities and Exchange Commission and declared effective on 03 November 2021. The offering was made through a prospectus. Copies thereof may be obtained from BofA Securities, NC1-004-03-43; 200 North College Street, 3rd Floor, Charlotte, North Carolina 28255-0001, Attention: Prospectus Department or by email at , Morgan Stanley & Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at .

    This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities law of any such state or Jurisdiction.

    This communication and the information contained herein is made solely for information purposes only and does not constitute or form part of a prospectus or any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities of Evotec, in any jurisdiction. Neither this communication, nor any part of it, nor the fact of its distribution, shall form the basis of, or be relied on in connection with, any contractual commitment or investment decision in relation to the securities of Evotec, in any jurisdiction, nor does it constitute a recommendation regarding any such securities.

    The placement of the securities mentioned in this communication is directed only at persons in member states of the European Economic Area (the " EEA ") who are " Qualified Investors " within the meaning of the Prospectus Regulation EU 2017/1129 (" Prospectus Regulation ") (" Qualified Investors "). Any person in the EEA who acquires the securities in any offer (an " Investor ") or to whom any offer of the securities is made will be deemed to have represented and agreed that it is a Qualified Investor.

    In the United Kingdom, this communication is only directed at persons who are "qualified investors" within the meaning of Article 2 of the Prospectus Regulation as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 who are also (i) investment professionals falling within Article 19(5) of the UK Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the " Order ") or (ii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2) of the Order (all such persons together being referred to as " Relevant Persons "). Any investment or investment activity to which this communication relates is available only to Relevant Persons in the United Kingdom and will only be engaged with such persons. Any person in the United Kingdom who is not a Relevant Person should not act or rely on this communication or any of its contents.

    ABOUT EVOTEC SE
    Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this "Data-driven R&D Autobahn to Cures" for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 4,000 highly qualified people. The Company's 14 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on Twitter @Evotec and LinkedIn.

    FORWARD-LOOKING STATEMENTS
    This announcement contains forward-looking statements concerning future events, including the offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding completion of the offering. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

    INVESTOR RELATIONS CONTACT:
    ,
    T. +49.(0)40.560 81-775
    F. +49.(0)40.560 81-333

    SOURCE: Evotec AG



    View source version on accesswire.com:
    https://www.accesswire.com/671898/Evotec-SE-Announces-Closing-of-Public-Offering

    View Full Article Hide Full Article
View All Evotec SE News